Supplementary Table 1.

Inclusion and exclusion criteria.

1) Inclusion criteria

Age ≥20 At least 3 months from KT Patients who have been on Tac±anti-proliferating agents+steroid for at least 3 months MDRD eGFR ≥50 ml/min/1.73 m2 or serum creatinine <2.0 mg/dL The change of serum creatinine less than 30% Spot urine protein/creatinine ratio > 0.3 Patients who do not meet the criteria of PTDM at baseline (6 months from KT) Patients who agree to participate in this study

2) Exclusion criteria

Combined non-renal transplantation Re-transplantation ABO incompatible transplantation highly sensitized patients before transplantation (pre-transplant PRA titer >50% (either class I or class II), or pre-transplant T cell cytotoxicity crossmatch (+)) HLA-identical living related donor Diabetes mellitus before transplantation or PTDM at baseline Acute rejection within within 3 months Hypersensitivity to everolimus Gastrointestinal malabsorptive condition due to gastrectomy or diabetic gastroparesis HIV, HBsAg or HCV Ab (+) AST, ALT or total bilirubin >3 fold than normal value Absolute neutrophil count <1.5×109/L or WBC 2.5×109/L or platelet <75×109/L Clinically significant infection within 4 weeks at 6 months from KT Active malignancy, skin cancer, post-transplant lymphoproliferative disease Pregnancy, lactation, plan for another pregnancy within 12 months Major surgery within 4 weeks at 6 months from KT Another clinical study

MDRD – modification of diet in renal disease; eGFR – estimated glomerular filtration rate; PTDM – post-transplantation diabetes mellitus; PRA – panel-reactive antibody.